29 / 31
Dudas en CPNM estadio
III irresecable
Beneficio y toxicidad de IO + QT-RT concomitante
NCT03663166: phase I/II RT +CT +
Ipilimumab
à
Nivolumab
• Unresectable, Stage IIIA-B
NSCLC
• 18 years or older
• Tumor tissue
RT 60 Gy
Platinum based CT
IPI 1 mg/Kg day 1 and 28
Secondary
endpoint
• DMFS
• ORR
• OS
Primary endpoint
• DLT
• PFS 12m
Nivolumab 480mg
c/4w x 12 cycles